#United States #Class Action #Radnor #uniQure N.V. #QURE

Kessler Topaz Meltzer & Check, LLP Files Class Action Suit Against uniQure N.V.

On March 19, 2026, Kessler Topaz Meltzer & Check, LLP announced the filing of a securities fraud class action lawsuit against uniQure N.V., a biotechnology company known for its endeavors in developing gene therapies. The legal action targets investors who purchased uniQure shares between September 24, 2025, and October 31, 2025, a period characterized by purported misleading communications concerning the company's flagship gene therapy for Huntington's disease (HD).

Overview of the Allegations

Filed in the United States District Court for the Southern District of New York and titled Scocco v. uniQure N.V., the lawsuit highlights several claims made by the firm regarding uniQure's AMT-130, which is under development for treating Huntington’s disease. The essence of the complaint asserts that uniQure provided materially false or misleading information about its clinical trials and the implications for its Biologics License Application (BLA) with the FDA.

Kessler Topaz Meltzer & Check claims that during the specified class period, uniQure failed to disclose essential facts and made inflated statements about the success of its pivotal study and the regulatory approval timeline for AMT-130. It was alleged that:
1. The study's design was not entirely sanctioned by the FDA, calling into question the validity of its results.
2. Even with alleged positive outcomes, they would face delays in the BLA submission due to additional studies being necessary, which contradicted prior assurances given to investors.
3. The optimistic projections about the market readiness significantly lacked a grounding in reality, misleading investors about the company's true operational status and potential.

Impact on Investors

The fallout from these revelations was stark. On November 3, 2025, uniQure disclosed that the FDA had expressed reservations about the adequacy of the data provided for the BLA submission. This declaration precipitated a dramatic decline in the stock price, which plummeted by over 49%, dropping from $67.69 to $34.29 per share in a matter of days. This catastrophic loss left many investors seeking clarity and potential recourse for their financial damages.

Taking Action: What Affected Investors Can Do

For investors who acquired uniQure shares during the class period, there is a deadline of April 13, 2026, to file a motion to be appointed as lead plaintiff in the class action. Kessler Topaz Meltzer & Check offers complimentary case evaluations to those potentially affected by this situation. Interested investors can reach out to Jonathan Naji, Esq., via phone or email for further assistance and to discuss the possible implications of their investments, free of charge.

About Kessler Topaz Meltzer & Check, LLP

KTMC is recognized as a prominent law firm specializing in securities fraud class action lawsuits. With a robust track record of securing substantial recoveries for clients, they support individual and institutional investors alike, including major pension funds and international stakeholders. With offices located in both Pennsylvania and California, KTMC prides itself on its advocacy for investor rights.

For more detailed information regarding this case or for assistance related to your investment in uniQure, visit KTMC's website or contact them directly. Navigating the complex landscape of securities law can be daunting, but with the right legal support, investors can seek the justice they deserve.